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Combination treatment for non–small cell lung cancer (NSCLC) is becoming more popular due to the anticipation
that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients
for specific mutations in light of attempting to administer specific anticancer agents that are most effective. In this
study, we evaluate the anticancer and anti-angiogenic effects of low dose erlotinib-cisplatin combination in NSCLC
in vitro and in vivo. In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination
erlotinib-cisplatin treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-
type EGFR. In xenograft models, combination treatment also demonstrated greater inhibition of tumor growth
compared to individual treatment. The anti-tumor effect observed was secondary to the targeting of angiogenesis,
evidenced by decreased vascular endothelial growth factor (VEGF) levels and decreased levels of CD31 and
microvessel density. Combination treatment targets angiogenesis through down-regulation of the c-MYC/hypoxia
inducible factor 1-alpha (HIF-1α) pathway. In fact, cell lines with EGFR exon 19 deletions expressed high basal levels of c-
MYC and HIF-1α and correlate with robust responses to combination treatment. These results suggest that low dose
erlotinib-cisplatin combination exhibits its anti-tumor activity by targeting angiogenesis through the modulation of the c-
MYC/HIF-1α/VEGF pathway in NSCLC with EGFR exon 19 deletions. These findings may have significant clinical
implications inpatientswith tumorsharboringEGFRexon19deletionsas theymaybeparticularly sensitive to this regimen.
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Lung cancer is the leading cause of cancer-related deaths worldwide, and
non–small cell lung cancer (NSCLC) comprises about 85% of all types
of lung cancer [1]. Traditionally, patients with NSCLC are treated with
platinum-based chemotherapy agents such as cisplatin, which has
proven to improve overall survival [2]. Cisplatin imparts its anticancer
effects by inducing DNA cross-linking, DNA damage, and apoptotic
cell death. However, cisplatin is associated with significant side effects
given its lack of cell specificity; most commonly cisplatin toxicity is
associated with renal failure, ototoxicity, and/or neurotoxicity [2,3]. To
prevent systemic side effects, there is a need for chemotherapy drugs and
anticancer agents that target cancer cells and its pathologic pathways.
NSCLC is strongly associated with epidermal growth factor
receptor (EGFR) mutations. It is estimated that more than 60% of
NSCLC have EGFR mutations that lead to constitutive activation of
downstream pathways. The overexpression of EGFR has been shown
to have a direct correlation with poor prognosis, indicating that thismutation and pathologic mechanism may be a suitable target for
anticancer agents [4,5]. There have been great advancements in
developing small molecule inhibitors that specifically target EGFR.
Erlotinib is an EGFR-specific tyrosine kinase inhibitor (TKI)
approved for the clinical treatment of advanced stages of NSCLC
[6]. Erlotinib binds to EGFR and inhibits the activation of its
downstream signaling pathways involved in cell proliferation,
survival, angiogenesis, invasion, and migration [1,6].
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erlotinib treatment; however, patients develop acquired resistance to
erlotinib approximately 10 months after initial therapy [7,8]. The two
most recognized mechanisms that promote erlotinib acquired resistance
are T790Mpointmutation in exon 21 in EGFR andMET amplification
[9,10]. Although several othermechanisms have been identified (insulin-
like growth factor-1 and AXL tyrosine kinase receptor overexpression
and ABCG2 efflux of drug transporters), 30% of mechanisms remain
unknown [11–16]. Similarly, in the case of cisplatin, despite good initial
response, patients often develop chemotherapy resistance [17–19]. It is
shown that cisplatin treatment results in increased EGFR phosphorylation
and activation of its downstream target kinases in cisplatin-resistant breast
cancer cells [20]. Additionally, cisplatin can cause EGFR translocation to the
nucleus where it contributes to resistance by restoring DNA repair
activity [21,22]. Therefore, overcoming these resistant mechanisms through
combination treatment is of great interest.
Angiogenesis is a fundamental step for tissue growth and
maturation, and this process is often pathologically used by tumors
to grow, expand, and metastasize [23]. One of the most potent
growth factors that mediate angiogenesis is vascular endothelial
growth factor (VEGF) as it recruits and stimulates the growth of
endothelial cells, leading to increased vascularity [23,24]. Angioge-
nesis has been understood to be an important therapeutic target, and
drugs targeting VEGF such as a bevacizumab has been developed and
approved for clinical use [24]. Over the past several years, there have
been studies suggesting that both erlotinib and cisplatin individually
are able to target angiogenesis in various cancers [25–28]. However,
details regarding their mechanisms of action and the effects of
combining these two drugs have yet to be elucidated.
In a prior study, we showed that low dose erlotinib-cisplatin
combination treatment was able to induce synergistic cell death in
EGFR-mutated PC9 cells in vitro [29]. In this study, we investigated
the effects of erlotinib-cisplatin combination treatment in multiple
NSCLC cell lines with different EGFR statuses, and we also evaluated
its effectiveness in xenograft mouse models. In addition, we examined
whether combination erlotinib-cisplatin treatment is able to inhibit
angiogenesis at greater degrees compared to single drug treatment alone.
The effected pathway and regulatory proteins were also identified.
Materials and Methods
Cell Lines and Cell Culture
Human lung adenocarcinoma cell lines (A549, NCI-H292, H1650
and HCC827) were purchased from American Type Culture Collection
(Manassas, VA). PC9 and H3255 cells were kind gifts from Dr Halmos
from Columbia University and Dr Minna from UT Southwestern,
respectively. The EGFRmutation status of the main cell lines of interest
is reported in Figure 1A. Cells were maintained in RPMI 1640 media
containing 10%FBS and 37°C in a humidified incubator with 5%CO2.
Cell Viability Assay
Four treatment groups were devised according to a 2 × 2 factorial
experimental design [30]: control, erlotinib-alone, cisplatin-alone,
and erlotinib-cisplatin combination. Drug treatment concentrations
were chosen as previously described [29]. All cell lines were treated for
2 days and cell viability assay was measured using the Alamar Blue
Assay (Invitrogen, Carlsbad, CA). Combination index (CI) values
were calculated to determine for additive or synergism effects of
treatment as previously described [29,30].Xenograft Mice
The protocol was approved by the Institutional Animal Care andUse
Committee of the University of California, Davis (Protocol No.
16985), and this study was conducted according to the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. This study used 4- to 5-week-old female athymic nu/nu mice
from Charles River Laboratories International, Inc (Wilmington, MA).
They were acclimated for 1 week on arrival to our animal facility before
testing was initiated. The local committee for animal care approved all
animal studies. A total of 5 × 106 cells was suspended in 100 μl of
serum-free RPMI 1640 mixed with 100 μl of phenol-red free Matrigel
(BD Biosciences, San Jose, CA) and subcutaneously injected into the
flank. When tumor volume reached 100 cm3, mice were randomly
assigned to four treatment groups: control, erlotinib (15 mg/kg),
cisplatin (2 mg/kg), or combination of erlotinib and cisplatin (each
group containing five to six mice). Treatments were administered every
2 days by intraperitoneal injection. The length and width of the tumor
were measured using a digital caliper, and the volume of the tumor was
calculated using the formula: length × (width)2/2. In addition, before
each treatment, mice were weighed to monitor signs of drug toxicity.
On day 15 of treatment, the mice were sacrificed and tumors were
harvested for histologic and molecular analyses.
Western Blot Analysis
For in vitro samples, cells were prepared and Western blot was
performed as described previously [29]. In vivo tumor samples were
first crushed using a homogenizer in a protein cocktail containing
RIPA buffer (Millipore, Billerica, MA), protease inhibitors, and
phosphatase inhibitors (Sigma-Aldrich, St Louis, MO). Then, the
samples were centrifuged for 15 minutes at 14,000 rpm and 4°C. The
following preparation steps follow the same protocol as the in vitro
samples [29]. Blots were probed with anti-CD31, anti-VEGF
(Abcam, Cambridge,MA), anti-c-MYC, or anti–hypoxia inducible factor
1-alpha /(HIF-1α) (Abcam) and their appropriate secondary antibodies.
Blots were then probed with anti–β-actin (Sigma-Aldrich) or anti-TBP
(Cell Signaling Technology, Boston, MA), and the β-actin or TBP to
protein ratios were calculated to allow for standardized comparisons.
Cytoplasmic and Nuclear Fractionation
Samples were collected for nuclear and cytoplasmic fractions using
NE-PER nuclear and cytoplasmic extraction reagents exactly according
to the manufacturer’s instructions (Pierce Chemical, Rockford, IL).
After cytoplasmic extracts were collected, pellets were incubated with
NER reagents for 40 minutes on ice and were vortexed for 15 seconds
every 10minutes. Then, the samples were centrifuged for 10minutes at
14,000 rpm in a cold room, and the supernatant that contained the
nuclear extract were collected and prepared for Western blot analysis.
Hematoxylin and Eosin Staining
Tissue sections were stained with hematoxylin and eosin (H&E) by
the UC Davis Cancer Center Biorepository Department.
Immunohistochemistry
All harvested tumors were fixed with 4% paraformaldehyde
overnight in a cold room and then embedded with paraffin. On the
day of immunohistochemistry, the paraffin-embedded tumor tissues
were deparaffinized and rehydrated. Sections were pretreated with
heat-mediated antigen retrieval using Tris/EDTA pH 9.0 buffer.
Then, sections were incubated with hydrogen peroxidase blocking
agent (Abcam) for 20 minutes at room temperature and washed with
Figure 1. Erlotinib-cisplatin was most effective in cells harboring EGFR exon19 deletion in vitro and in vivo. (A) A report of the EGFR and
PTEN status of multiple NSCLC cell lines is shown. (B) Cell viability was quantified with Alamar Blue Assay, and the control group was set
to 100% as the standard group. Two-day combination treatment led to synergistic cell death in PC9 and HCC827 cell lines (P b .0001; CI =
0.45 and P = .0005; CI = 0.98, respectively). Combination treatment was not effective in A549, H292, and H1650 cell lines. (C) In the
treatment of tumors in xenograft models, there was a significant difference in tumor volume starting at day 5. Combination treatment
resulted in the smallest mean tumor volume throughout the treatment course and at the end of the treatment course (day 15) when
compared to control, erlotinib alone, and cisplatin alone treatment groups (P = .001, P = .003, and P = .027, respectively). (D) All four
groups had similar body weight indicating minimal toxicity. For (C) and (D), specific mean tumor volume and body weights are shown at
indicated time points (±SD, n=4-5mice each group); * indicates a P value less than .05, ** indicates a P value less than .01, *** indicates
a P value less than .001, and **** indicates a P value less than .0001.
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to the manufacturer’s protocol for ABC detection kit (Abcam), 3,3′-
diaminobenzidine (DAB) staining was performed to detect CD31
(Abcam; 1:200 overnight incubation at 4°C).
Immunofluorescence Assay
Cells were plated onto a sterile glass cover and 2-day treatment
started 24 hours following plating. The cells were then fixed and
prepared as previously described [29]. Tumor samples from the mice
were prepared as described in the Immunohistochemistry section up
until staining with DAB. Primary antibody for anti–c-MYC wasincubated overnight in a dark room at 4°C and then next day with
Alexa Fluor 488 antibody (1:2000; Invitrogen) for 1 hour at room
temperature. In addition, 4′,6-diamidino-2-phenylindole (DAPI;
Vector Laboratories, Burlingame, CA) was added to stain the nuclei.
All images were captured using Zeiss LSM700 confocal microscope
(Carl Zeiss, Jena, Germany); and the same setting was applied to all
images for consistency. Image analysis was done in a blinded fashion.
Microvessel Density Quantification
Due to CD31's endothelial cell specificity, it is the most common
marker to detect angiogenesis and is widely used to detect the
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Microscope was used to visualize tumor sections stained with CD31.
Microvessel density (MVD) was quantified using ImageJ, and the
percentage area of CD31 was calculated by imaging four different
20× high power fields through the hotspot method [32,33].
In Vivo Matrigel Plug Angiogenesis Assay
In vivo angiogenesis assay was tested through the use of the Matrigel
plug assay. Matrigel (500 ul; BD Biosciences) was mixed with
recombinant human VEGF 165 and Heparin-binding EGF-like
growth factor (HB-EGF) (R&D Systems, Inc, Minneapolis, MN),
and then appropriate drugs were added: vehicle, erlotinib (15 mg/kg),
cisplatin (2 mg/kg), or combination of erlotinib and cisplatin (each
group containing fourmice).Matrigelmixeswere injected subcutaneously
into the ventral abdomen ofmice.Mice were then sacrificed, andMatrigel
plugs were removed on day 21. Each plug was weighed, and following
manufacturer’s protocol, Drabkin's solutions (Sigma-Aldrich) were added
and incubated for 30 minutes at room temperature. The hemoglobin
contents in the Matrigel plugs were then read at 540 nm and analyzed.
Statistical Analysis
All statistical analyses in this study were performed using Prism
Software (La Jolla, CA). Analysis of variance and two-tailed Student’s
t test were performed to determine significant differences between
groups. A P value less than .05 was considered to be the threshold for
significance for this study, and all experiments were performed
independently at least three times to reach adequate power to detect
significant differences when present.
Results
Combination Treatment and Its Effects in EGFR Wild-Type
and Mutated NSCLC Cell Lines
Previously, we have shown that low dose erlotinib-cisplatin
combination treatment induces synergistic cell death in PC9 cells
in vitro [29]. As PC9 cells harbor an EGFR mutation, we tested
whether the synergistic killing effects of erlotinib-cisplatin combina-
tion is dependent on EGFR status. This was done by measuring cell
death following combination treatment in multiple NSCLC cell lines
with different EGFR statuses. The known EGFR status of the cell
lines can be seen in Figure 1A. Three of the cell lines harbor EGFR
mutations: PC9 and HCC827 have exon 19 deletions, and H1650
has both an exon 19 deletion and a PTEN null mutation. A549 and
NCI-H292 harbor wild-type EGFR.
As HCC827 cells have the same EGFR mutation as PC9 cells, we
expected that combination treatment would also lead to synergistic
cell death in HCC827. When HCC827 cells underwent combination
treatment, there was 71.1% cell survival (Figure 1B). This survival
rate was significantly lower than cells treated with erlotinib (88.1%,
P = .018) and cisplatin (91.2%, P = .010). The treatment effect with
erlotinib-cisplatin combination in HCC827 cells was synergistic
(CI =0.98) like the observations seen in PC9 cells (CI = 0.45). In the
H1650 cells, combination treatment did not induce statistically
significant differences in cell death (100.7%) compared to control
(100.0%), erlotinib (98.3%), or cisplatin (101.0%; Figure 1B).
To further assess whether combination treatment was effective for
other types of genetic alteration of EGFR, we also tested combination
treatment in the H3255 cell line harboring the L858R missense
mutation. Similar to PC9 and HCC827 cells, synergistic cell death was
observed in H3255 cells with erlotinib-cisplatin combination treatment.Relative to control (100%), cell survival after treatment with erlotinibwas
77% (P = .003), that with cisplatin was 103% (P = .147), and that with
erlotinib-cisplatin combination was 49% (P = .001; data not shown).
A549 and H292 cell lines (wild-type EGFR) did not demonstrate
significant differences in cell survival among the four treatment groups
(Figure 1B). In the A549 cell line, cell survival was similar among the
four groups: control (100.0%), erlotinib (91.0%), cisplatin (97.0%),
and combination (93.2%). In H292 cells, cell survival was lower with
combination treatment (82.4%) than control (100.0%), erlotinib
(87.4%), and cisplatin (86.4%), but this was not statistically significant.
These results suggest that erlotinib-cisplatin combination treatment is
most effective in cell lines with EGFR mutations.
Combination Treatment and Inhibition of Tumor Growth in
PC9 Xenograft Mice
PC9 cells were selected as the cell line of choice to be implanted
into the xenograft mice because combination effect was most
profound among this cell line. At day 5 of treatment, tumor volumes
started to demonstrate significant differences among the four groups
(P = .006), and these differences continued throughout the 15-day
course of treatment: day 7 (P = .003), day 9 (P = .0004), day 11 (P =
.002), day 13 (P = .0002), and day 15 (P = .0002; Figure 1C ).
Combination treatment resulted in ongoing shrinkage of tumor
volume from its initial size of 100 mm3 and consistently had the
smallest tumor volume at each measured time point. In contrast, the
control group continued to grow linearly, and the single treatment
groups continued to grow gradually. On day 15, the combination
group had significantly smaller mean tumor volume (81.8 mm3)
compared to control (470.2 mm3; P = .001), erlotinib (203.0 mm3;
P = .003), and cisplatin (158.2 mm3; P = .027). None of the
treatment groups demonstrated a weight loss of more than 10%,
indicating no significant signs of toxicity (Figure 1D) [34]. This
supports that erlotinib-cisplatin combination is not only effective
in vitro but also acts as an effective anti-cancer regimen in vivo as well.
Combination treatment demonstrates greater tumor inhibition than
either single agent alone without being additionally toxic.
Combination Treatment and Its Effect on Vascularity
It is noteworthy that during harvesting and gross examination of
the resected tumors, there was less blood loss among the tumors that
underwent combination treatment. To verify whether this was
secondary to the presence of less vasculature, H&E staining of the
tumor samples was performed to grossly detect vascularity. The
combination group had the least amount of blood vessels among the
treatment groups (P = .0001; Figure 2A). Complementary to the
H&E staining, CD31 was identified by DAB staining to measure
MVD (Figure 2A). The control group had the highest MVD,
followed by cisplatin, then erlotinib, and then combination.
Compared to control and erlotinib- and cisplatin-treated groups,
combination treatment had significantly less MVD (P = .007, P =
.010, and P = .040, respectively; Figure 2B). In vivo Matrigel plug
angiogenesis assays were performed to test the effects of combination
treatment on hemoglobin contents. Matrigels containing combina-
tion drugs resulted in the least hemoglobin contents compared to
Matrigels containing vehicle, erlotinib, and cisplatin (P = .0003, P =
.040, and P = .012, respectively; Figure 2C). Western blot analysis
further verified these findings. The combination group had the lowest
levels of CD31 and this was significantly lower than control (P =
.007), erlotinib (P = .040), and cisplatin (P = .010; Figure 2D).
Figure 2. Erlotinib-cisplatin combination treatment led to a significant decrease in tumor vascularity in xenograft mice. (A) H&E staining of
tumors demonstrated the least amount of vasculature in the combination group. (B) MVD was quantified in tumor samples stained with
CD31 (using DAB). The combination group showed the lowest MVD (0.2%) compared to control (2.8%), erlotinib alone (1.1%), and
cisplatin alone (1.2%) treated groups. (C) In vivo angiogenesis was performed byMatrigel plug assay. The Matrigel plug with combination
drugs had the lowest hemoglobin contents (0.41) compared to Matrigel plug with control (0.63), erlotinib alone (0.63), and cisplatin alone
(0.61). (D) CD31 levels from tumor samples were analyzed through Western blot analysis. Compared to tumors from control (P = .007),
erlotinib (P = .04), and cisplatin (P = .01) groups, significantly lower CD31 levels were measured in the combination treatment group.
The numerical density of CD31 is indicated below the bands; * indicates a P value less than .05, ** indicates a P value less than .01,
*** indicates a P value less than .001, and **** indicates a P value less than .0001.
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VEGF is one of the most potent proangiogenic peptides known, and
modulation of this peptide will likely have significant consequence on
angiogenesis. On treatment of PC9 cells in vitro, both erlotinib and
cisplatin individually resulted in lower levels of VEGF compared to
control (P = .007 and P = .005). However, combination treatment had
the greatest effect in lowering VEGF levels among four treatment
groups (P = .004; Figure 3A). Interestingly, however, the reduction of
VEGF with combination treatment was most profound in vivo. While
individual drug treatments did not demonstrate the similar effectiveness
in vivo as it did in vitro, combination treatment resulted in significantly
lower VEGF levels compared to control (P = .003), erlotinib (P = .041),
and cisplatin (P = .024; Figure 3B). Here, we demonstrate that low dose
erlotinib and cisplatin are both able to modulate VEGF levels, but as
individual treatments, they are minimally effective. Rather, when given
in combination it becomes very effective in decreasing VEGF levels
both in vitro and even more so in vivo.Down-Regulation of Angiogenesis through Inhibition of the
c-MYC/HIF-1α/VEGF Pathway
To further understand how combination treatment is able to
regulate angiogenesis through the down-regulation of VEGF, we
investigated the regulatory pathways that control the production of
VEGF. HIF-1α is a transcription factor that induces VEGF
expression in hypoxic conditions and therefore promotes the process
of angiogenesis [35]. Details regarding the regulation of HIF-1α in
normal and cancer cells can be seen in Figure 4A. Therefore, we
sought to see if there were changes in nuclear HIF-1α levels with drug
treatments. In vitro, there were significantly lower levels of nuclear
HIF-1α in the erlotinib alone and combination group compared to
control (P = .045 and P = .008, respectively); the combination group
demonstrated the greatest decrease in HIF-1α. Cisplatin-treated cells
had similar levels as control (Figure 4B). A similar trend was also seen
in vivo. However, parallel to the observed effects in vivo on VEGF,
individual treatments of erlotinib alone and cisplatin alone did not
result in significant changes of HIF-1α levels. Rather only
Figure 3. Erlotinib-cisplatin combination treatment led to decreased VEGF levels in vitro and in vivo. (A) The changes in VEGF levels in PC9
cells were quantified through Western blot analysis. There were significantly lower VEGF levels in combination-treated cells among four
treatment groups (P = .004). (B) Similarly, through Western blot, combination treatment had the most profound decrease in VEGF levels
and was significantly lower than control (P= .003), erlotinib alone (P= .041), and cisplatin alone (P= .024); * indicates a P value less than
.05, ** indicates a P value less than .01, *** indicates a P value less than .001, and **** indicates a P value less than .0001.
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HIF-1α and its effect was quite profound (P = .002; Figure 4B).
HIF-1α can be induced and stabilized in normoxia by various
oncogenes in cancer cells (Figure 4A). Recent studies have reported
that HIF-1α may be induced by deregulated c-MYC in NSCLC
[36,37]. Therefore, we hypothesized that c-MYC levels may be
affected by combination treatment that subsequently also affect HIF-
1α and VEGF production. There were no significant differences in
nuclear c-MYC levels among control, erlotinib alone, and cisplatin
alone groups both in vitro and in vivo (Figure 5A). However,
combination treatment led to a drastic decrease in nuclear c-MYC
level in vitro (P b .0001) and in vivo (P = .001). These results were
further verified with immunofluorescence staining of c-MYC in PC9
cells and tumor samples (Figure 5B). These correlations suggest that
low dose combination treatment is very effective in downregulating
the c-MYC/HIF-1α pathway, while individual treatments are less
likely to target c-MYC on its own.
Basal c-MYC and HIF-1α Levels in Cells with EGFR Exon
19 Deletion and Response to Erlotinib-Cisplatin Combination
Treatment
We have shown that combination treatment is able to decrease
VEGF levels by targeting the c-MYC/HIF-1α pathway in PC9 cells and
xenograft models. Thus, we wanted to assess whether the degree of
effectiveness of combination treatment is dependent on basal levels of
c-MYC and HIF-1α. We hypothesized that cells with higher levels of
c-MYC andHIF-1αwill be the best responders.With the cell lines used
in the cell viability experiments (Figure 1A), we measured their
associated c-MYC and HIF-1α levels. PC9 and HCC827 had the
highest basal c-MYC levels (Figure 6A). Furthermore, PC9 and
HCC827 cell lines also expressed the highest HIF-1α levels (Figure 6B).
The two cell lines with the highest basal levels of c-MYC andHIF-1α
were PC9 and HCC827, and these cell lines were also associated with
the cell death following combination treatment. In fact, both showedsynergistic cell death with combination treatment (Figure 1B). These
findings strongly suggest that the degree in which combination
treatment inhibits the c-MYC/HIF-1α pathway and the subsequent
modulation of VEGF and angiogenesis may depend on basal levels of
c-MYC/HIF-1α; if a cell has high basal c-MYC and HIF-1α levels,
combination treatment seems to be more effective.
Discussion
Activating EGFR mutations are present in more than 60% of all
NSCLCs and most often are due to an exon 19 deletion or exon 21
L858R point mutation [38,39]. These mutations occur in the
tyrosine kinase domain of the EGFR in a manner that lead to constant
phosphorylation of the receptor and activation of downstream cascade
pathways (such as the RAS, Phosphoinositide 3-kinase, and STAT
signaling pathways) that are important in regulating cell proliferation and
growth [39,40]. TKIs such as erlotinib and gefitinib were designed to
target the mutated region of EGFR, thus inhibiting its activity [41–43].
The Food and Drug Administration initially approved both drugs;
however, gefitinib was withdrawn from the United States and Europe
due to lack of significant benefit on survival, whereas erlotinib is still
being used in patients with NSCLC [38,44,45]. It has been shown that
patients with NSCLC harboring an activating EGFR mutation are
dramatically sensitive and respond very well to erlotinib treatment
[38,44]. Therefore, in this study, we wanted to test whether we can
augment erlotinib treatment with the combination of cisplatin to achieve
even better outcomes in NSCLC harboring EGFR mutations.
With the optimism that combination treatment is superior to
individual drug treatment, there is a growing interest in studying the
effects of combining chemotherapeutic agents with specific cancer
inhibitors. Combining different agents can be more effective (additive
or synergistic) as multiple pathways can be targeted [46]. However,
past studies have suggested that the benefits of combination treatment
are selective and that only particular subsets of cancers are
exceptionally sensitive. Okabe et al. demonstrated that the synergistic
Figure 4. HIF-1α–VEGF pathway was markedly inhibited by combination treatment as demonstrated in vitro and in vivo. (A) A simplified
diagram describing the regulation of the HIF-1α and VEGF pathway in normal and cancer cells is shown. (B) Nuclear HIF-1α protein levels
were measured withWestern blot. Erlotinib-cisplatin combination led to a significant down-regulation of nuclear HIF-1α levels in both PC9
cell line and xenograft mouse models, while individual drug treatment was minimally effective. The numerical density of nuclear HIF-1α is
indicated below the bands.
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observed in EGFR mutant (exon 19 deletion) NSCLC cell lines with
MET amplification but not in cell lines with an additional EGFR
T790M mutation [47]. Similarly, Minami et al. reported that
combination of cisplatin and olaparib induced synergistic anti-cancer
effects only in PTEN-deficient NSCLC cell lines [48]. According to
these observations, it is likely that specific drug combinations are most
effective for a specific phenotypic and genotypic subset of cancers.
In this study, we found a similar observation in which cancer cell
lines with EGFR exon 19 deletion (PC9 and HCC827) responded
best to low dose erlotinib-cisplatin combination treatment. In
addition, erlotinib-cisplatin combination resulted in synergistic cell
death in an NSCLC cell line with the L858R missense mutation.
Both the exon 19 deletion and L858R missense mutation occur in
proximity to the ATP-binding site of the tyrosine kinase domain, and
both result in constitutive activation of EGFR mediated pathways
[49]. Therefore, the effect of combination erlotinib-cisplatin had
similar effects (synergistic cell death) in cell lines with either mutation
type. While in EGFR wild-type cell lines (A549 and H292),
erlotinib-cisplatin combination induced minimal cell death. Cancer
cells can become fully dependent on a single oncogenic pathway for
survival and targeting of this pathway can be lethal; among the cell
lines tested, it is the EGFR signaling pathway. This phenomenon is
also known as “oncogene addiction” [38]. An interesting observation
is that the H1650 cell line was not affected by combination therapy
even though it harbored the exon 19 deletion. However, it also did
have a null PTEN mutation, and according to the current literature,
the additional PTEN mutation that H1650 cell line harbors acts as a
mechanism for TKI resistance that may explain why combination
treatment was not as effective [50–52]. These findings led us to
conclude that low dose erlotinib-cisplatin combination is likelydependent on EGFR status and most effective in cancers with EGFR
exon 19 deletions.
As in vitro, combination treatment was also effective in vivo.
Xenograft mice with implanted PC9 cells demonstrated significantly
greater inhibition of tumor growth and shrinkage when treated with
erlotinib-cisplatin combination. Tumors in the single drug–treated
groups continued to grow throughout their treatment courses. Other
than causing cell death, there are likely additional mechanisms in
which combination treatment is able to inhibit tumor growth; yet
these mechanisms have to be elucidated or reported.
Angiogenesis has been recognized as an important event as it plays
an essential role for tumor growth and survival [53]. In fact, in
NSCLC, there is a direct correlation between decreased survival with
high levels of angiogenesis and VEGF [35,53,54]. Angiogenesis is
controlled by a variety of growth factors, and the most important
proangiogenic peptide is VEGF [53]. For this reason, there continues
to be active research and development of anti-angiogenic agents such
as VEGF receptor TKIs and a monoclonal antibody that targets
VEGF [24,53]. Intuitively, previous studies have shown that the
combination of an anticancer agent with an anti-angiogenic agent
results in enhanced inhibition of tumor growth and angiogenesis
[55,56]. This is somewhat expected considering one of the drugs
specifically targets angiogenesis. In this study, we show for the first
time that low dose erlotinib-cisplatin combination treatment is able to
profoundly inhibit angiogenesis through down-regulation of VEGF
in vitro and even more effectively in vivo.
A few studies have reported that erlotinib is able to inhibit
angiogenesis in pancreatic adenocarcinoma and malignant peripheral
nerve sheath tumors. Cisplatin is also able to do so in hepatocellular
carcinoma and transitional cell cancer [25–28]. However, the
pathways and regulatory proteins in which erlotinib and cisplatin
Figure 5. Erlotinib-cisplatin treatment led to a significant decrease in nuclear c-MYC in PC9 cells and xenograft tumors. (A) Combination
treatment resulted in the greatest inhibition of c-MYC both in vitro and in vivo. (B) Immunofluorescence staining of c-MYC in PC9 cells and
tumor samples further delineates and demonstrates the differences in c-MYC levels among treatment groups. Significantly less green
fluorescence is observed in combination-treated groups in vitro and in vivo compared to three other groups (blue, DAPI; green, c-MYC).
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findings reveal that erlotinib-cisplatin combination treatment targets
the c-MYC/HIF-1α pathway that can regulate the production of
VEGF and angiogenesis. In normoxia, HIF-1α is rapidly degraded
through proteasomal pathways. However, under hypoxic conditions,
HIF-1α stabilizes, accumulates in the cytoplasm, and enters the
nucleus where it induces genes associated with angiogenesis,
including VEGF [3,24,36,57]. In cancer cells, however, it has been
reported that HIF-1α is regulated by both an oxygen-dependent
manner (hypoxia) and oxygen-independent factors such as activated
oncogenes [36,37]. c-MYC, a proto-oncogene, is believed to be one
of the candidate oncogenes that can induce the expression of HIF-1α
and therefore promote angiogenesis [37]. Our findings suggest that
combination treatment downregulates c-MYC and HIF-1α conse-
quently inhibiting VEGF and angiogenesis.
Prior studies have shown that c-MYC can be upregulated by EGFR
through pathways such as the Ras-Raf-Erk pathway and therefore result
in the promotion of angiogenesis through HIF-1α and VEGF
[37,56,58–60]. Thus, it is mechanistically clear how erlotinib is able
to hinder angiogenesis. The known associations between erlotinib and
cisplatin combination suggest that the down-regulation of c-MYC
increases susceptibility and sensitivity to cisplatin through induction of
reactive oxygen species–mediated apoptosis and inhibition of MLH1
and MSH2 mismatch repair proteins, all leading to cell death [40,61].As cisplatin works through DNA damage, the inhibition of mismatch
repair proteins likely contribute significantly to the observed synergistic
cell death when cisplatin is given in combination with erlotinib.
However, it does not explain how combining cisplatin with erlotinib is
able to further downregulate angiogenesis through the c-MYC–HIF-
1α–VEGF pathway. Future studies are ongoing to decipher underlying
mechanism of cisplatin.
The effect of combination treatment on angiogenesis was most
profound in vivo. It is indeterminate why individual drug treatments
were only mildly to moderately effective in vitro and in vivo, while
combination treatment worked in both models. This difference may
be secondary to the fact that tumor cells in the xenograft mice were
exposed to “real” hypoxic conditions when tumors reached a
threshold size in which oxygen diffusion becomes inefficient. In
this scenario, the tumors most likely further upregulate HIF-1α
(which is a “normal” response to hypoxic conditions) to promote
production of VEGF and angiogenesis. Therefore, these tumors have
very high levels of proangiogenic regulators. Changes in HIF-1α
levels following single low dose drug treatment may be less able to be
measured as their effect is small.
Researchers have been searching for amplifications and/or up-
regulation of certain genes that contribute to drug sensitivities
[62–64]. Here, we found an interesting result in which cell lines with
EGFR exon 19 deletion mutations had higher levels of c-MYC and
Figure 6. High basal levels of c-MYC and HIF-1α were correlated with greater response to treatment. (A) Western blot was performed
to measure the basal level of c-MYC in NSCLC cell lines (shown in Figure 1A). PC9 and HCC827 (P= .0002) had the highest basal level of
c-MYC, followed by A549 (P = .050), H292 (P= .080), and H1650 (P= .007). (B) HCC827 (P = .220) and PC9 also had the highest basal
levels of HIF-1α, followed by H292 (P= .045), A549 (P= .050), and H1650 (P= .0002); * indicates a P value less than .05, ** indicates a
P value less than .01, *** indicates a P value less than .001, and **** indicates a P value less than .0001.
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to erlotinib-cisplatin combination treatment. These findings are
significant in two ways. First, EGFR mutations that lead to constant
EGFR activity were associated with higher c-MYC and HIF-1α
levels. This supports that EGFR may be able to induce the up-
regulation of c-MYC and HIF-1α. Second, response to treatment can
be enhanced by targeting “oncogene addiction.” As the cell lines with
EGFR mutations likely rely heavily on this mechanism to proliferate
and grow, targeting this pathway will likely have significant negative
consequence for the cell. This phenomenon is similar to the basis
behind personalize therapy for cancer. Through genetic analysis,
physicians are attempting to identify specific mutations and aberrant
pathways that may be susceptible to certain treatment agents to
improve response and prognosis [65–67].
Conclusions
This study has demonstrated that erlotinib-cisplatin combination is also
effective in vivo, and combination treatment is most effective in NSCLC
cells with EGFR exon 19 deletion that is associated with high c-MYC
and HIF-1α levels. In addition, for the first time, we show that erlotinib-
cisplatin combination treatment effectively targets angiogenesis through the
inhibition of the c-MYC–HIF-1α–VEGF signaling pathway. Taken
together, the preclinical data of our study provide a novel understanding in
regard to the underlying mechanism of erlotinib-cisplatin combination
therapy in the treatment of NSCLC with EGFR exon 19 deletions.
Furthermore, this study opens opportunities for further research on this
topic and encourages clinicians to test this combination in patients with
NSCLC harboring EGFR exon 19 deletions.
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